2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
Abstract
Use of an effective amount of a compound 2,4-pirimidindiamínico according to structural formula (Id) for preparing a medicament for inhibiting proliferation of a cancer cell: Structural formula to (Id) including salts, hydrates, solvates and N-oxides, wherein: Z1 is selected from N and CH; Z2 is selected from NH, O, S and S (O) 2; R16 is selected from hydrogen and methyl; R19 is selected from the group consisting of hydrogen, alkyl (C1-C8), methyl and Rd; R20 is selected from the group consisting of hydrogen, alkyl (C1-C8), methyl and Rd; where each Rd is independently selected from monohydroxy (C1-C8) and dihydroxy (C1C8); R24 is selected from hydrogen and methyl; R41 is selected from alkyl (C1-C8), methyl; (C1-C8), methoxy, halo, chloro, trifluoromethyl and -CH2OH; R42 is selected from hydrogen, (C1-C8), methyl, hydroxy, (C1-C8), methoxy, halo, chloro, trifluoromethyl, trifluoromethoxy, -OCH2C (O) NHRa, and ** ** ** Formula Formula ** and R43 is selected from hydrogen, (C1-C8), methyl, hydroxy, (C1-C8), methoxy, halo, chloro, trifluoromethyl, trifluoromethoxy, -OCH2C (O) NHRa, -OCH2C (O) ORa ** Formula Formula ** and ** ** where each R12 is independently selected from the group consisting of alkyl (C1-C8) alkyl, aryl, - ORa, -NRcRc, -C (O) Ra, -C (O) ORa and -C (O) NRcRc; each R is independently selected from the group consisting of hydrogen, alkyl (C1-C8), (C3-C8), cycloalkyl (C3-C8) alkyl (C1-C4) alkyl, phenyl and benzyl; and each Rc is independently selected from the group consisting of hydrogen, (C1-C8) and cycloalkyl (C3-C8), or alternatively, may take two Rc together with the nitrogen atom to which they are attached to form a saturated ring 5-7 membered optionally includes an additional 1-2 heteroaromatic groups selected from O, NRa, NRa-C (O) Ra, NRa-C (O) ORa and NR-C (O) NR provided that (i) when R42 ** ** Formula is or then R43 ** ** Formula not be ** ** Formula or and (ii) when R43 is ** ** · Formula then R42 or will not be ** ** Formula
Term
Term ended
Expired 6 August 2024, 2.1 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
155 members in 31 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 49400803 | United States of America | P | |
| 57253404 | United States of America | P | |
| 2004025409 | United States of America | W |
Members155
| Document | Office | Kind | |
|---|---|---|---|
| WO2005012294A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2005013996A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2004265288A1 | Australia | A1 | |
| CA2533377A1 | Canada | A1 | |
| WO2005016893A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2005113398A1 | United States of America | A1 | |
| WO2005013996A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2005016893A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2005063722A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2005192301A1 | United States of America | A1 | |
| US2005209224A1 | United States of America | A1 | |
| US2005234049A1 | United States of America | A1 | |
| CA2566531A1 | Canada | A1 | |
| WO2005118544A2 | World Intellectual Property Organization (WIPO) | A2 | |
| GB0523012D0 | United Kingdom | D0 | |
| WO2005012294A8 | World Intellectual Property Organization (WIPO) | A8 | |
| US2006035891A1 | United States of America | A1 | |
| WO2005118544A3 | World Intellectual Property Organization (WIPO) | A3 | |
| NO20060992L | Norway | L | |
| ITMI20052171A1 | Italy | A1 | |
| EP1656372A2 | European Patent Office (EPO) | A2 | |
| FR2877944A1 | France | A1 | |
| KR20060056353A | Republic of Korea | A | |
| AU2005307849A1 | Australia | A1 | |
| CA2580150A1 | Canada | A1 | |
| WO2006055561A2 | World Intellectual Property Organization (WIPO) | A2 | |
| GB2420559A | United Kingdom | A | |
| EP1663242A2 | European Patent Office (EPO) | A2 | |
| IL173299D0 | Israel | D0 | |
| DE102005054092A1 | Germany | A1 | |
| US2006167249A1 | United States of America | A1 | |
| EP1694652A1 | European Patent Office (EPO) | A1 | |
| BRPI0413018A | Brazil | A | |
| US7122542B2 | United States of America | B2 | |
| CN1849318A | China | A | |
| HK1091209A1 | Hong Kong, China | A1 | |
| JP2007500722A | Japan | A | |
| JP2007501793A | Japan | A | |
| EP1763514A2 | European Patent Office (EPO) | A2 | |
| JP2007514775A | Japan | A | |
| NO20073068L | Norway | L | |
| IL181923D0 | Israel | D0 | |
| US2007167439A1 | United States of America | A1 | |
| US2007179140A1 | United States of America | A1 | |
| KR20070085571A | Republic of Korea | A | |
| EP1824489A2 | European Patent Office (EPO) | A2 | |
| RU2006106180A | Russian Federation | A | |
| US2007225495A1 | United States of America | A1 | |
| MX2007005807A | Mexico | A | |
| JP2007538092A | Japan | A | |
| US2007299060A1 | United States of America | A1 | |
| US2008009484A1 | United States of America | A1 | |
| US2008009494A1 | United States of America | A1 | |
| US2008021020A1 | United States of America | A1 | |
| US2008027045A1 | United States of America | A1 | |
| US2008051412A1 | United States of America | A1 | |
| ES2296477A1 | Spain | A1 | |
| CN101171012A | China | A | |
| ZA200601460B | South Africa | B | |
| WO2006055561A3 | World Intellectual Property Organization (WIPO) | A3 | |
| RS20060073A | Serbia | A | |
| JP2008520580A | Japan | A | |
| GB2420559B | United Kingdom | B | |
| BRPI0516795A | Brazil | A | |
| ZA200702180B | South Africa | B | |
| SG145698A1 | Singapore | A1 | |
| HK1114338A1 | Hong Kong, China | A1 | |
| US7452879B2 | United States of America | B2 | |
| US2008312438A1 | United States of America | A1 | |
| RU2007122381A | Russian Federation | A | |
| US7511137B2 | United States of America | B2 | |
| RU2356901C2 | Russian Federation | C2 | |
| US2009137589A1 | United States of America | A1 | |
| US2009176981A1 | United States of America | A1 | |
| US7560466B2 | United States of America | B2 | |
| US7582648B2 | United States of America | B2 | |
| UA88660C2 | Ukraine | C2 | |
| US2009318687A1 | United States of America | A1 | |
| NZ545270A | New Zealand | A | |
| UA91000C2 | Ukraine | C2 | |
| US7754714B2 | United States of America | B2 | |
| NZ554419A | New Zealand | A | |
| US7858633B2 | United States of America | B2 | |
| US7863286B2 | United States of America | B2 | |
| EP1824489B1 | European Patent Office (EPO) | B1 | |
| US7868013B2 | United States of America | B2 | |
| AT494280T | Austria | T | |
| ATE494280T1 | Austria | T1 | |
| US7884111B2 | United States of America | B2 | |
| AU2011200367A1 | Australia | A1 | |
| DE602005025803D1 | Germany | D1 | |
| RU2416604C2 | Russian Federation | C2 | |
| DK1824489T3 | Denmark | T3 | |
| EP1663242B1 | European Patent Office (EPO) | B1 | |
| AT506953TThis record | Austria | T | |
| ATE506953T1 | Austria | T1 | |
| ES2359416T3 | Spain | T3 | |
| SI1824489T1 | Slovenia | T1 | |
| DE602004032446D1 | Germany | D1 | |
| US2011152518A1 | United States of America | A1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 4780274
Titles2
- German
- 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN UND VERWENDUNGEN ALS ANTIPROLIFERATIVE MITTEL
- English
- 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS
Classification
- CPC, 16
- C07D498/04
- A61K31/4353
- A61K31/505
- A61K31/506
- A61P35/00
- C07D239/48
- A61P35/04
- C07D401/12
- A61P43/00
- C07D401/14
- C07D403/12
- C07D405/12
- C07D413/12
- C07D413/14
- C07D417/12
- C07D417/14
- IPC, 3
- A61K31 4353
- A61K31 505
- A61K31 506